Cabergoline
An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.
Also Known As:
1-((6-allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; 1-Ethyl-2-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'-beta-carbonyl)urea diphosphate; Cabaser; Cabaseril; Cabergoline Diphosphate; Dostinex; FCE 21336; FCE-21336; Galastop; Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propen-1-yl)-, (8beta)-
Networked: 1145
relevant articles (208 outcomes,
217 trials/studies)
Relationship Network
Drug Context: Research Results
Experts
1. | Colao, Annamaria:
38 articles
(01/2023 - 06/2002)
|
2. | Pivonello, Rosario:
28 articles
(01/2023 - 06/2002)
|
3. | Lombardi, Gaetano:
18 articles
(01/2009 - 06/2002)
|
4. | Shimon, Ilan:
13 articles
(02/2024 - 02/2007)
|
5. | Auriemma, Renata S:
12 articles
(01/2023 - 01/2013)
|
6. | Wu, Zhe Bao:
12 articles
(01/2022 - 11/2015)
|
7. | Molitch, Mark E:
11 articles
(02/2017 - 10/2002)
|
8. | Colao, A:
10 articles
(03/2015 - 01/2000)
|
9. | Hofland, Leo J:
9 articles
(01/2023 - 05/2004)
|
10. | Casulari, Luiz Augusto:
9 articles
(06/2019 - 01/2004)
|
Related Diseases
Related Drugs and Biologics
Related Therapies and Procedures